PW MEDTECH (01358) announced its interim results. The company's net profit attributable to owners was approximately 66 million yuan, a decrease of 6.0% year-on-year.

PW MEDTECH (01358) announced its mid-term performance for 2025, with revenue of approximately 414 million yuan, a year-on-year increase of 22.4%; the company's attributable net profit is about 66 million yuan, a year-on-year decrease of 6.0%. Earnings per share are 4.44 cents, and the mid-term dividend is 4.4 Hong Kong cents per share. The announcement stated that the growth in revenue was mainly due to strong sales in the blood purification business, as well as the first-time revenue from the regenerative medical biomaterial business, partially offset by a decrease in sales from the infusion device business. The decrease in net profit was mainly due to a decrease in operating profit and financial income.